The earnings call presented significant positive developments, including a notable reduction in net loss, a strong cash position, and successful clinical trial progress for soquelitinib. However, increased R&D expenses and delays in trial result reporting were challenges. Overall, the positive aspects, particularly related to clinical advancements and financial improvements, seem to outweigh the negatives.

Company Guidance

During the Corvus Pharmaceuticals Third Quarter 2025 Business Update and Financial Results Conference Call, CFO Leiv Lea outlined key financial metrics, noting that research and development expenses totaled $8.5 million, a $3.3 million increase from the prior year, primarily due to costs associated with soquelitinib development. The net loss for Q3 2025 was $10.2 million, significantly reduced from a $40.2 million loss in Q3 2024. Stock compensation expenses rose to $1.2 million from $700,000. Corvus reported $65.7 million in cash and equivalents as of September 30, 2025, with current funds expected to support operations into Q4 2026. CEO Richard Miller discussed clinical progress, highlighting the completion of enrollment for extension Cohort 4 in a Phase I trial and the upcoming Phase II trial for atopic dermatitis, expected to begin in early Q1 2026.

Significant Reduction in Net Loss

The net loss for Q3 2025 was $10.2 million, a substantial decrease from the $40.2 million loss in Q3 2024.

Strong Cash Position

Corvus had cash, cash equivalents, and marketable securities totaling $65.7 million as of September 30, 2025, up from $52 million at the end of 2024.

Successful Enrollment in Phase I Trial for Soquelitinib

Enrollment in the extension Cohort 4 of the Phase I trial for soquelitinib was completed, with results expected in January 2026.

Upcoming Phase II Trial for Atopic Dermatitis

The initiation of the Phase II atopic dermatitis trial for soquelitinib is on track for early Q1 2026, involving approximately 200 patients globally.

Positive Efficacy Data for Soquelitinib

Cohort 3 of the Phase I trial showed a mean percent reduction of EASI score of 64.8%, with notable patient responses.

Presentation at ASH for T Cell Lymphoma

The final results from the Phase I/Ib clinical trial of soquelitinib for relapsed/refractory T cell lymphomas will be presented at the ASH meeting in December.

Corvus Pharmaceuticals (CRVS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRVS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 05, 2026	2025 (Q4)	-0.13 / -	-0.18	―	―	―
Nov 04, 2025	2025 (Q3)	-0.13 / -0.12	-0.6	80.00% (+0.48)	―
Aug 07, 2025	2025 (Q2)	-0.13 / -0.10	-0.07	-42.86% (-0.03)	―
May 08, 2025	2025 (Q1)	-0.12 / -0.13	-0.12	-8.33% (-0.01)
Mar 25, 2025	2024 (Q4)	-0.12 / -0.18	-0.14	-28.57% (-0.04)	―
Nov 12, 2024	2024 (Q3)	-0.11 / -0.60	-0.12	-400.00% (-0.48)	―
Aug 06, 2024	2024 (Q2)	-0.12 / -0.07	-0.14	50.00% (+0.07)	―
May 06, 2024	2024 (Q1)	-0.14 / -0.12	-0.17	29.41% (+0.05)	―
Mar 19, 2024	2023 (Q4)	-0.12 / -0.14	-0.21	33.33% (+0.07)	―
Nov 07, 2023	2023 (Q3)	-0.12 / -0.12	-0.32	62.50% (+0.20)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRVS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$7.64	$7.53	-1.44%
Aug 07, 2025	$4.13	$4.31	+4.36%
May 08, 2025	$3.35	$4.43	+32.24%
Mar 25, 2025	$3.93	$3.35	-14.76%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Corvus Pharmaceuticals Inc (CRVS) report earnings?

Corvus Pharmaceuticals Inc (CRVS) is schdueled to report earning on Mar 05, 2026, TBA (Confirmed).

What is Corvus Pharmaceuticals Inc (CRVS) earnings time?

Corvus Pharmaceuticals Inc (CRVS) earnings time is at Mar 05, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CRVS EPS forecast?

CRVS EPS forecast for the fiscal quarter 2025 (Q4) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing